---
title: "Nafamostat - Cystic Fibrosis"
sidebar: mydoc_sidebar
permalink: db12598-mesh-d003550-1.html
toc: false 
---


Path ID: `DB12598_MESH_D003550_1`
{% include image.html url="images/db12598-mesh-d003550-1.png" file="db12598-mesh-d003550-1.png" alt="db12598-mesh-d003550-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C032855 | nafamostat | Drug |
| InterPro:IPR001873 | Epithelial sodium channel | GeneFamily |
| GO:0070254 | mucus secretion | BiologicalProcess |
| HP:0006536 | Airway obstruction | PhenotypicFeature |
| MESH:D003550 | Cystic fibrosis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Nafamostat | DECREASES ACTIVITY OF | Epithelial Sodium Channel |
| Epithelial Sodium Channel | POSITIVELY REGULATES | Mucus Secretion |
| Mucus Secretion | POSITIVELY CORRELATED WITH | Airway Obstruction |
| Airway Obstruction | MANIFESTATION OF | Cystic Fibrosis |
|---------|-----------|---------|

Comment: Nafamostat mesilate is expected to work by reducing ENaC activity, stimulating the clearance of mucus and relieving the symptoms of the disease.

Reference: 
  - [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu310782](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu310782)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/4413](https://pubchem.ncbi.nlm.nih.gov/compound/4413)
